

Harbour BioMed, CTTQ unite to discover, develop and commercialize Innovative Biologics

07 May 2019 | News

Global collaboration focused on new antibody treatments in the fields of oncology and immunology



Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. (CTTQ) are entering into a strategic alliance to discover, develop and commercialize next-generation biologics for multiple therapeutic targets in oncology and immunology.

The collaboration will combine Harbour BioMed's discovery capabilities, including its transgenic mouse technologies for generating fully human antibodies, with CTTQ's preclinical development resources and expertise. The companies will be responsible for clinical development and commercialization of therapeutic candidates emerging from the collaboration in their respective regions.

Harbour BioMed will be responsible for the United States, Japan, and the rest of the world outside, while CTTQ will have responsibility for Greater China and Europe. The companies will pay royalties to each other based on sales in their respective territories. Additional financial terms were not disclosed.